Numerion Labs

Artificial intelligence for drug discovery.

Y CombinatorWinter 2015ActiveHealthcareDrug Discovery and DeliveryAI-powered Drug DiscoveryDeep LearningBiotechDrug discovery

What they do

Problem

Drug discovery is slow and costly due to complex biology and inefficient identification of viable drug candidates.

Solution

Numerion Labs provides an AI-driven drug discovery platform using cutting-edge machine learning combined with computational chemistry and structural biology to accelerate candidate discovery and optimization.

Who it's for

Pharmaceutical companies and biotech drug discovery teams use it to identify and optimize new therapeutics.

Founders

Alex Levy

Founder

Leveraging AI to revolutionize the physical sciences, Alex Levy is the CEO and co-founder of Atmo, the leading company integrating AI into global weather forecasting. Previously, he co-founded Atomwise (W15), a pioneering AI company in small molecule drug discovery, boasting over 800 active programs and $1 billion in pharmaceutical partnerships. An alumnus of the University of Toronto, he began his career by leading a computer vision research lab within the Computer Science Department.